Batten Disease Treatments
Find Batten Disease Treatments
Brand Name
Brineura
Generic Name
Cerliponase
View Brand Information FDA approval date: April 27, 2017
Form: Kit
What is Brineura (Cerliponase)?
BRINEURA is indicated to slow the loss of ambulation in pediatric patients with neuronal ceroid lipofuscinosis type 2 , also known as tripeptidyl peptidase 1 deficiency. BRINEURA is a hydrolytic lysosomal N-terminal tripeptidyl peptidase indicated to slow the loss of ambulation in pediatric patients with neuronal ceroid lipofuscinosis type 2 , also known as tripeptidyl peptidase 1 deficiency.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
There is no clinical trials being done for this treatment